Alexandria Pharmaceuticals
AXPH
AXPH
Alexandria Pharmaceuticals and Chemical Industries will pay coupon No. 20 at EGP 4.5 per share on Monday, Oct. 20.
Shareholders of record until the close of trading on Wednesday, Oct. 15 are eligible for this dividend.
The company’s ordinary general meeting had endorsed the board report, as well as financial statements and profit/loss statement for the fiscal year that ended on June 30, 2014.
Shareholders approved the proposed dividend distribution for FY13/14 at EGP 4.5 per share and the distribution of 500 thousand bonus shares worth EGP 5 million to be financed from FY13/14 earnings.
The company’s board had proposed increasing authorized capital from EGP 50 million to EGP 100 million as well as issued and paid-in capital from EGP 45 million to EGP 50 million through the issuance of 500,000 bonus shares.
Accordingly, the company’s total number of shares will increase to 50 million from 45 million.
Alexandria Pharmaceuticals had posted financial statements for the fiscal year that ended on June 30, 2014, showing that net profit declined 0.3% to EGP 47.8 million, compared with EGP 47.9 million a year earlier.
The company’s financial results for the 11-month period from July 1, 2013 till May 31, 2014 had shown net profit of EGP 45.4 million, with a slight rise by 0.02% compared with EGP 45.3 million in the same period a year earlier.
Shareholders of record until the close of trading on Wednesday, Oct. 15 are eligible for this dividend.
The company’s ordinary general meeting had endorsed the board report, as well as financial statements and profit/loss statement for the fiscal year that ended on June 30, 2014.
Shareholders approved the proposed dividend distribution for FY13/14 at EGP 4.5 per share and the distribution of 500 thousand bonus shares worth EGP 5 million to be financed from FY13/14 earnings.
The company’s board had proposed increasing authorized capital from EGP 50 million to EGP 100 million as well as issued and paid-in capital from EGP 45 million to EGP 50 million through the issuance of 500,000 bonus shares.
Accordingly, the company’s total number of shares will increase to 50 million from 45 million.
Alexandria Pharmaceuticals had posted financial statements for the fiscal year that ended on June 30, 2014, showing that net profit declined 0.3% to EGP 47.8 million, compared with EGP 47.9 million a year earlier.
The company’s financial results for the 11-month period from July 1, 2013 till May 31, 2014 had shown net profit of EGP 45.4 million, with a slight rise by 0.02% compared with EGP 45.3 million in the same period a year earlier.
Source:
Mubasher
